Humanization of a strategic CD3 epitope enables evaluation of clinical T-cell engagers in a fully immunocompetent in vivo model

T-cell engagers (TCEs) are a growing class of biotherapeutics being investigated in the clinic for treatment of a variety of hematological and solid tumor indications. However, preclinical evaluation of TCEs in vivo has been mostly limited to xenograft tumor models in human T-cell reconstituted immu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zorn, Julie A., Wheeler, Matthew L., Barnes, Ralston M., Kaberna, Jim, Morishige, Winse, Harris, Marek, Huang, Richard Y.-C., Lohre, Jack, Chang, Yu Ching, Chau, Bryant, Powers, Kathleen, Schindler, Ian, Neradugomma, Naveen, Thomas, Winston, Liao, Xiaoyun, Zhou, Yinhan, West, Sean M., Wang, Feng, Kotapati, Srikanth, Chen, Guodong, Yamazoe, Sayumi, Kosenko, Anastasia, Dollinger, Gavin, Sproul, Tim, Rajpal, Arvind, Strop, Pavel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894342/
https://www.ncbi.nlm.nih.gov/pubmed/35241687
http://dx.doi.org/10.1038/s41598-022-06953-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894342/
https://www.ncbi.nlm.nih.gov/pubmed/35241687
http://dx.doi.org/10.1038/s41598-022-06953-7

Ejemplares similares